While much attention has been focused lately on breakthrough drugs for treating Alzheimer’s disease, Altoida CEO Marc Jones believes their digital assessment technology will play a crucial role in determining, even before first symptoms appear, whether a case of mild cognitive impairment (MCI) will escalate into Alzheimer’s within a year.
Empowering Primary Care Physicians With Digital Biomarkers For Early Alzheimer’s Detection
Altoida CEO Discusses Company’s Use Of AR, ML To Predict Neurological Disease Progression
Altoida CEO Mark Jones has high hopes that the company’s digital assessment tool will be approved by the FDA to be used along with blood biomarker testing by primary care doctors to help predict Alzheimer’s disease before patients show symptoms.
